採用
Bluebird Bio
Bluebird Bio
Develops gene therapies for severe genetic disorders.
Gene Therapy
Biotechnology
Clinical Research
Genetic Engineering
Cell Biology
募集中のポジション
0件のポジション
現在募集中のポジションはありません
製品・サービス
ZY
Zynteglo
Gene Therapy
Zynteglo
Gene Therapy
Skysona
Gene Therapy
SK
Skysona
Gene Therapy
LE
LentiGlobin
Gene Therapy
LE
Lenti-D
Gene Therapy
Lenti-D
Gene Therapy Research
BB
bb1111
Cell Therapy
bb2121 (ide-cel)
CAR-T Cell Therapy
bb21217
CAR-T Cell Therapy
Gene Therapy Manufacturing Services
Manufacturing Services
BB
bb21217
Cell Therapy
類似企業
Moderna
Public
mRNA medicines.
Cambridge, Massachusetts
1,001-5,000
Valuation $47B
NYU Langone
Public
Academic medical center
New York, NY
10,001+
Tandem Diabetes
Public
Insulin pump manufacturer
San Diego, California
501-1,000
Valuation $2.1B
57 open jobs
Johnson & Johnson
Public
Caring for the world, one person at a time.
New Brunswick, New Jersey
10000+
Valuation $400B
1618 open jobs
Merck
Public
Multinational pharmaceutical company.
Rahway, New Jersey
10,001+
Valuation $208B
683 open jobs
Medidata (Dassault)
Acquired
Develops and markets software as a service (SaaS) for clinical trials.
New York City, Medidata
1,001-5,000
Valuation $5.8B
ニュース＆話題
All
X
News
HN
YouTube
Bluebird Bio net income 2016-2019 - Statista
Statista
News
·
1ヶ月前
bluebird bio sees higher offer for company from Ayrmid Pharma - MSN
Source: MSN
google-news
·
2ヶ月前
Taming the Complexity of CGT Commercialization: 5 Keys to a Workable Operating Model - Pharmaceutical Executive
Pharmaceutical Executive
News
·
3ヶ月前
PepGen Inc.
PepGen Inc. appoints Joseph Vittiglio as Chief Business and Legal Officer, bringing over 20 years of experience in the biotechnology sector. He previously worked at bluebird bio and Finch Therapeutics and will help advance PepGen's PGN-EDODM1 program. *PepGen Inc. [PEPG](https://www.google.com/finance/quote/PEPG:NASDAQ) is headquartered in Boston, MA.* [Source](https://www.sec.gov/Archives/edgar/data/1835597/000119312525310544/pepg-ex99_1.htm)
·
4ヶ月前
·
1
Beam Therapeutics ($BEAM) Valuation Model: Why Fair Value is $125 Based on 2025 Liquidity & ASH Data
(Disclaimer: I am long $BEAM. This is not financial advice. I have had my valuation models cited by financial news algorithms before, but do your own research.) The Executive Summary (TL;DR) We are currently witnessing a mathematical dislocation in Beam Therapeutics ($BEAM). • The Trap: Official Short Interest (20.55M shares) now exceeds the estimated "Tradable Float" (~14M shares). • The Catalyst: ASH 2025 Data (Saturday) confirms "Best-in-Class" safety & efficacy, while competitors ($N
·
4ヶ月前
·
7
·
5
もっと見る (残り15件)
総閲覧数
0
応募クリック数
0
模擬応募者数
0
スクラップ
0
レビュー
3.8
10件のレビュー
ワークライフバランス
3.2
報酬
3.5
企業文化
4.1
キャリア
2.8
経営陣
2.3
68%
友人に勧める
良い点
Supportive team and colleagues
Great team culture and collaboration
Good benefits and compensation
改善点
Poor management and lack of direction
Limited career advancement opportunities
High pressure and demanding workload
給与レンジ
56件のデータ
Director
Junior/L3
Mid/L4
Senior/L5
Director
3件のレポート
$246,359
年収総額
基本給
$214,225
ストック
-
$246,359
$246,359
面接体験
2件の面接
難易度
3.0
/ 5
期間
2-5w
内定率
50%
体験
ポジティブ 50%
普通 50%
ネガティブ 0%
面接プロセス
1
Application Review
2
HR Screen
3
Hiring Manager Interview
4
Panel Interview
5
Offer
連絡先・所在地